Scorpion Therapeutics is expanding the potential of precision medicine to cancer patients. Using their fully integrated discovery platform that uses cancer biology, medicinal chemistry, chemical proteomics and molecular biophysics, Scorpion is advancing drug discovery, small molecule design and target identification to rapidly create selective small molecule compounds against an unprecedented spectrum of targets. Scorpion is currently focusing on validated oncogene targets as well as undruggable targets and novel cancer targets. Their lead program, STX-478, is an oral inhibitor of PI3K-alpha that is in clinical stages as a monotherapy for patients with breast cancer.

Scorpion Therapeutics


      
        




    09/14/2024

    

      
      Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche
      Read More
    

Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations - BioSpace

 Ins & Outs: C-suite changes across biotechs - BioProcess Insider 

Odyssey starts journey with $218M for 7 assets across cancer, inflammation with IFM, Scorpion founder at the helm - Fierce Biotech

Scorpion is honored to support #BreastCancerAwarenessMonth and share the promising results from our recent clinical study presented at #ESMO.

Our Phase 1/2 trial of STX-478 demonstrates potentially best-in-class PI3Kα inhibition, showing a 23% overall response rate in HR+/HER2- metastatic breast cancer, and significant tumor reductions in patients with advanced solid tumors. Our early, differentiated signals of monotherapy efficacy compare favorably to other pathway inhibitors. This milestone reflects our unwavering commitment to improving patients' lives through next-generation precision oncology.

Learn more about our findings and ongoing efforts: https://bit.ly/3Y4iB25  

A well-funded cancer drug startup brings on GSK’s Axel Hoos as CEO - BioPharma Dive


      
        




    04/04/2023

    

      
      Scorpion Partners Two Assets With Pierre Fabre To Prioritize Investment In A Third
      Read More
    

Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer - PR Newswire

03/8/2022 Press Release Scorpion Therapeutics To Present Mutant-selective PI3Kα Program At AACR Annual Meeting 2022 Read More

Chutes & Ladders—GlaxoSmithKline's oncology head leaves for biotech Scorpion Therapeutics - Fierce Biotech


      
        




    07/16/2024

    

      
      Scorpion raises $150M with sights on the next wave of targeted therapies
      Read More
    

04/8/2022 Press Release Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data Supporting the Development of Its Potentially Best-in-Class Mutant-Selective PI3Kα Inhibitor for the Treatment of Solid Tumors at the AACR Annual Meeting 2022 Read More

 Scorpion Therapeutics to Present at Jefferies Healthcare Conference 

 Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline 

02/25/2021 Press Release Scorpion Therapeutics Announces Leadership Change Read More

10/24/2023 Press Release Scorpion Therapeutics Appoints Precision Medicine Leader Jeff Albers as Strategic Advisor Read More

We are pleased to share clinical program updates for our mutant-selective PI3Ka inhibitor STX-478 that underscore our commitment to advancing precision oncology.

At #SABCS24, we are presenting updated data from our Phase 1/2 study of STX-478. The results highlight robust PI3Kα pathway inhibition, favorable safety, and a clear dose-response relationship. These findings reinforce STX-478’s potential to transform outcomes for patients with a variety of solid tumors.

Additionally, we have entered into a new clinical trial collaboration with #Pfizer to evaluate Pfizer’s investigative selective-CDK4 inhibitor, in combination with STX-478 and fulvestrant in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer in the frontline metastatic setting.

Together with our partners, we are dedicated to shaping the future of cancer therapy by delivering innovative, targeted solutions for those who need them most. Learn more: https://bit.ly/4fbaw13  

 Boston Therapeutics rakes in $150m Series C 

06/29/2022 Press Release Scorpion Therapeutics Nominates STX-721 as EGFR-EXON-20 Development Candidate with a Best-in-Class Profile Read More


      
        




    07/07/2021

    

      
      GSK Oncology Exec Hoos Heads Back To Biotech As CEO Of Scorpion Therapeutics
      Read More
    


      
        




    10/31/2022

    

      
      Scorpion Therapeutics Accelerates Precision Oncology 2.0 for More Patient Populations
      Read More
    

12/8/2022 Press Release Scorpion Therapeutics Presents Preclinical Data for Potential Best-in-Class PI3Kα Inhibitor at San Antonio Breast Cancer Symposium Read More

11/22/2021 Press Release Scorpion Therapeutics Announces Appointment Of Brian Piper As Chief Financial Officer Read More

Scorpion Therapeutics Raises $150M in Series C Financing - FinSMEs

10/10/2023 Press Release Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer Read More


      
        




    07/16/2024

    

      
      Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline
      Read More
    


              DrugMap: A quantitative pan-cancer analysis of cysteine ligandability
            

09/15/2024 Press Release Scorpion Therapeutics Presents Initial Clinical Data from Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024 Read More

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors - Business Wire

Scorpion snaps up $150M in series C funds to widen clinical plans for cancer pipeline - Fierce Biotech

Scorpion Therapeutics Launches with $108 Million to Advance Precision Oncology 2.0 - Business Wire

10/12/2022 Press Release Scorpion Therapeutics to Present Preclinical Proof-of-Concept Data for Highly Selective, Next-Generation Exon 20 Mutant EGFR Inhibitor at 34th EORTC-NCI-AACR Symposium Read More

 New TP53 activators disclosed by Scorpion Therapeutics 


      
        




    07/19/2022

    

      
      Axel Hoos Wants to Take Small Molecules Further at Scorpion, Leaving Big Pharma in the Dust
      Read More
    

07/7/2021 Press Release Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D. Read More

 Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer 

 Scorpion Therapeutics patents new EGFR and HER2 inhibitors for cancer 

Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer - citybiz


      
        




    01/13/2021

    

      
      J.P. Morgan 39th Annual Healthcare Conference
      Read More
    

01/5/2022 Press Release Scorpion Therapeutics Receives Biospace Nextgen Bio “class Of 2022” Recognition Read More

 Scorpion Therapeutics Raises $150M in Series C Financing 

04/3/2023 Press Release Scorpion Therapeutics Nominates STX-241 as Potentially Best-in-Class Fourth-Generation EGFR Inhibitor Development Candidate for the Treatment of Non-Small Cell Lung Cancer Read More

scorpiontx.com

10/26/2022 Press Release Scorpion Therapeutics Presents Preclinical Proof-of-Concept Data for STX-721, a Next-Generation Exon 20 Mutant EGFR Inhibitor, at the EORTC-NCI-AACR Symposium 2022 Read More

Odyssey raises epic $101M to push programs off to clinical sea - Fierce Biotech

 Scorpion Therapeutics Presents Preclinical Data for STX-241, a 

Former CEO of IFM Therapeutics launches new precision medicine startup with $108M - The Business Journals

At Scorpion, we're committed to giving back to our local communities and making a positive impact. Recently, our employees came together to build children's bikes for donation to East Boston Social Centers and the Redwood City Pal Center.

This community service event was more than just team building; it was about supporting local organizations and bringing joy to children in need. We're grateful to all the Scorpions who made this event a success. Let's continue to support and uplift our communities together. 

Today, we are one step closer to potentially improving the lives of patients living with non-small cell lung cancer (#NSCLC). We’re excited to announce that the first patient has been treated in a Phase 1/2 first-in-human dose-escalation, dose-optimization and dose-expansion trial of STX-241, a highly differentiated, orally bioavailable, highly selective tyrosine kinase inhibitor targeting EGFR Exon 19 or 21 mutations with the co-occurring C797S mutation. STX-241 was discovered by Scorpion and is the second program being developed in collaboration with Pierre Fabre Laboratories. 
Learn more: https://bit.ly/3Nf3PzB
 
#NSCLC #PrecisionOncology

New TP53 activators disclosed by Scorpion Therapeutics - BioWorld Online

AstraZeneca pays Hoos-helmed Scorpion $75M to take the sting out of undruggable cancer targets - Fierce Biotech


      
        




    01/12/2021

    

      
      With Biotech Funding At ‘All-time High,’ Scorpion Scoops Up $162 Million
      Read More
    

Today at #ESMO2024, we announced initial clinical data from our Phase 1/2 Trial of STX-478 demonstrating potentially best-in-class mutant-selective PI3Kα inhibition for the treatment of advanced solid tumors
Learn more: https://bit.ly/3MLH4CX 

09/12/2022 Press Release Scorpion Therapeutics Appoints Michael Streit, M.D. as Chief Medical Officer Read More

Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline - Pulse 2.0

04/8/2021 Press Release Scorpion Therapeutics Appoints Guy Padbury, Ph.D. As Chief Development Officer Read More

10/25/2021 Press Release Scorpion Therapeutics Expands Executive Leadership Team With Three Key Appointments Read More

Rx Rundown: Novartis, Goldman Sachs, Klick Health and more - MM+M Online

Sanofi's Michael Streit departs to be cancer-focused Scorpion's first CMO - Fierce Biotech

Pierre Fabre in $618m EGFR deal with Scorpion - BioProcess Insider

Scorpion Therapeutics Announces New CEO Axel Hoos, M.D., Ph.D. - Business Wire

01/7/2021 Press Release Scorpion Therapeutics Announces Oversubscribed $162 Million Series B Financing Read More

Armed with $270M in capital, Scorpion Therapeutics aims to broaden the reach of precision oncology - MedCity News

OnKure hitches Reneo's ride to Nasdaq, with $65M PIPE to boot - Fierce Biotech


      
        




    01/12/2021

    

      
      Gary Glick, Keith Flaherty Now Have $270m To Realize Their Vision For Precision Oncology 2.0™ — We’ll Just Have To Wait For The Details
      Read More
    

We’re headed to San Antonio and look forward to sharing clinical data from our Phase 1/2 STX-478 trial during a Poster Spotlight Session (PS7-02) on Wed, Dec 11 at #SABCS24. Join us to uncover insights shaping the future of #PrecisionOncology. 

We hope to see you there! Check out our session details: https://bit.ly/3D3Erux 

 Scorpion Therapeutics Announces Discovery Scientific Advisory Board 

 Chutes & Ladders—GlaxoSmithKline's oncology head leaves for biotech Scorpion Therapeutics 


      
        




    04/04/2023

    

      
      Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets
      Read More
    

Scorpion Therapeutics Announces $150 Million Series C Financing to Advance Leading Clinical-stage Precision Oncology Pipeline - Business Wire

 Pierre Fabre Laboratories and Scorpion Therapeutics Annou... 

10/26/2020 Press Release Scorpion Therapeutics Launches With $108 Million To Advance Precision Oncology 2.0™ Read More

Scorpion Therapeutics Presents Initial Clinical Data From Its Phase 1/2 Trial of STX-478 Demonstrating Potentially Best-in-Class Mutant-Selective PI3Kα Inhibition for the Treatment of Advanced Solid Tumors at ESMO Congress 2024 - Business Wire

Scorpion Therapeutics debuts with $108M to 'put the sting in cancer' - Fierce Biotech

12/10/2024 Press Release Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Ka Inhibitor STX-478 Read More

Chutes & Ladders—New year, new CEO at Scorpion Therapeutics - Fierce Biotech


      
        




    07/07/2021

    

      
      In GSK’s Hoos, Scorpion Gains Oncology Pathfinder To Match Its $270m War Chest
      Read More
    


      
        




    01/12/2021

    

      
      Scorpion Therapeutics Strikes Major $162m Funding Round For ‘Precision Oncology 2.0™’
      Read More
    

10/8/2024 Press Release Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer Read More

Scorpion Tx Raises $150M For Cancer Pipeline with PI3Kα Inhibitor - Inside Precision Medicine

 Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline 

 Scorpion Therapeutics Announces Appointment of Brian Piper as Chief Financial Officer 

This Startup Raised $5.2 Million To Develop Blood Tests For Cancer - Forbes

Two local biotechs land $410M in investments as VC picks up - The Business Journals

Top Life Sciences Startups to Watch in 2022 - BioSpace

10/13/2023 Press Release Scorpion Therapeutics Presents Preclinical Data for STX-241, a Fourth-Generation EGFR Inhibitor, at the AACR-NCI-EORTC Symposium 2023 Read More

 Scorpion Therapeutics Inks $150 Million Series C 

Scorpion snags a Sanofi vet to lead the way to the clinic; All eyes on eli-cel as bluebird seeks a finance leader — again - Endpoints News

Scorpion Therapeutics Provides Clinical Program Updates for Its Mutant-Selective PI3Kα Inhibitor STX-478 - Business Wire

06/2/2022 Press Release Scorpion Therapeutics Announces Discovery Scientific Advisory Board Read More

Vision And Resilience, The Hallmarks Of Axel Hoos’ Leadership Approach - News & Insights


      
        




    04/04/2023

    

      
      Scorpion scores $65M as it lines up a partner to take EGFR programs global
      Read More
    

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer - PR Newswire

01/4/2024 Press Release Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team Read More

Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended to Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer - Business Wire


      
        




    10/26/2020

    

      
      Scorpion Therapeutics Debuts With $108m To ‘put The Sting In Cancer’
      Read More
    

Serial entrepreneur Gary Glick sells another one of his startups for $229M — this time to an unlikely buyer - Endpoints News

Scorpion snags $553M deal with Pierre Fabre for 2 preclinical lung cancer assets - Fierce Biotech

01/13/2022 Press Release Scorpion Therapeutics Enters Agreement With Astrazeneca To Discover, Develop And Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets Read More

This week, we celebrated a special milestone - our company anniversary. It's been four years of hard work and dedication, and we’re proud of our achievements that include: 

1. Advancing three compounds into development 
2. Building a fully-integrated chemistry discovery engine
3. Growing our Scorpion teams in Boston and South San Francisco 
4. Presenting a Trial-In-Progress at SABCS alongside Dr. Alberto Montero about our ongoing Phase 1/2 clinical study of STX-478 

Here’s to many years ahead of working to deliver transformative medicines to patients!

Scorpion Therapeutics

Business:

Drug notes:

About: